Key regions: Australia, Germany, United Kingdom, United States, France
The demand for immunosuppressants in Portugal has been on the rise in recent years.
Customer preferences: Patients suffering from autoimmune diseases, organ transplants, and other chronic diseases rely heavily on immunosuppressants to manage their conditions. In Portugal, these patients prefer to purchase branded drugs over generic ones due to the perception that they are more effective and of higher quality. However, the high cost of branded drugs is a significant factor that limits access to these medications.
Trends in the market: The Portuguese government has been implementing various measures to control healthcare costs, including promoting the use of generic drugs. This has led to an increase in the use of generic immunosuppressants in recent years. Additionally, the market has seen the introduction of biosimilars, which are expected to gain more market share in the coming years due to their lower cost compared to branded drugs.
Local special circumstances: The Portuguese healthcare system is primarily funded by the government, and patients are required to pay a co-payment when purchasing drugs. The co-payment amount is determined by the government and varies depending on the drug's price. This has led to a situation where patients with chronic conditions that require expensive medications may face significant financial burden.
Underlying macroeconomic factors: Portugal has been facing economic challenges in recent years, with high levels of unemployment and low GDP growth. The government has been implementing austerity measures to control spending, including healthcare spending. This has led to a situation where patients may face difficulties accessing expensive medications, including immunosuppressants. Additionally, the aging population in Portugal has led to an increase in the number of patients suffering from chronic diseases, which has contributed to the rising demand for immunosuppressants.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
